InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,751.07
(
0.90%
)
US TECH 100
19,476.00
(
1.10%
)
Dow Jones
42,352.75
(
0.81%
)
Brent Oil
77.97
(
0.00%
)
Bitcoin
62,183.83
(
0.18%
)
Post# of 253280
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

GrthzGd

Send PM Follow Ignore
Followers 15
Posts 1610
Boards Moderated 1
Alias Born 09/07/2010

GrthzGd

Re: DewDiligence post# 171343

Monday, 12/16/2013 2:13:47 PM

Monday, December 16, 2013 2:13:47 PM

Post# of 253280
Dew:
Given that two competing drugs-ABBV/ENTA and GILD's-are hitting the HCV treatment market at the same time, there must be a finite chance that a third one could also arise, and severely reduce both pricing and sales. Have you given any thought to this in your model?
GG
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up